ERBB2 and breast carcinoma: In the phase III PHOBE trial, progression-free survival (PFS) was significantly higher in the pyrotinib plus capecitabine arm than that in the lapatinib plus capecitabine arm for patients with advanced HER2-positive breast cancer (12.5 months vs 6.8 months, hazard ratio 0.39, p < 0.0001) (9).